Teva announces FDA acceptance of NDA filing for investigational short-acting beta-agonist inhaler (Albuterol MDPI)
14 July 2014 | By Teva
First breath-actuated dry-powder SABA inhaler to be accepted by FDA for review...
List view / Grid view
News
Abbott to sell its developed markets branded generics pharmaceuticals business to Mylan
14 July 2014 | By Abbott
Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company...
Roche’s investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening
14 July 2014 | By Roche
Roche announced that the Phase III coBRIM study met its primary endpoint...
Collaboration between Glatt and Innopharma labs for real-time in-line particle characterisation in batch/continuous production
11 July 2014 | By Innopharma Labs
Glatt and Innopharma Labs enter into a partnership to enable customers to profit from EyeconTM in-line particle characterisation...
Abbott builds long-term commitment in China
11 July 2014 | By Abbott
A proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott has made in China...
First ever dengue vaccine candidate to show efficacy against dengue fever and dengue haemorrhagic fever in Asia
11 July 2014 | By Sanofi
Sanofi Pasteur, the vaccines division of Sanofi announced the publication in The Lancet of the detailed results of its first landmark phase III dengue vaccine efficacy study conducted in five countries in Asia...
Bristol-Myers Squibb announces plans for third quarter submission of a biologics license application for opdivo® (nivolumab)
11 July 2014 | By Bristol-Myers Squibb
...an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma...
CloudScientific appointed as Cresset’s distributor in China
10 July 2014 | By kdm communications
Cresset announces the appointment of CloudScientific as distributor of their computational chemistry software in China...
CliniWorks forms a strategic alliance with Pfizer to develop a population health management platform with advanced analytics and patient care capabilities
10 July 2014 | By Pfizer
CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health...
Sanofi and Regeneron announce positive results from Phase 2b study of Dupilumab in patients with moderate-to-severe atopic dermatitis
10 July 2014 | By Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
Fraunhofer IME integrates European ScreeningPort to enhance its expertise and capabilities in drug discovery
9 July 2014 | By Fraunhofer
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
Actavis confirms Generic Ampyra® patent challenge
9 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Dalfampridine Extended-release Tablets, 10 mg...
Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting standard, increasing transparency
9 July 2014 | By Novartis
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013...
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
9 July 2014 | By
Summary: Acute Myeloid Leukaemia (AML) is an aggressive and devastating blood cancer. 1,2 It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World.1 The current standard of care is intensive chemotherapy, but many older patients cannot tolerate this therapeutic approach; their…
